4D Molecular Therapeutics, Inc.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $85.2M
- Net income
- -$140.1M
- Total assets
- $566.7M
- Market cap
- $451.7M
- Operating margin
- -187.2%
- Net margin
- -164.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $85.2M
- Operating expenses
- $244.8M
- Operating income
- -$159.5M
- Income tax
- $0
- Net income
- -$140.1M
- EPS (basic)
- $-2.42
- EPS (diluted)
- $-2.42
Balance sheet
- Total assets
- $566.7M
- Current assets
- $413.1M
- Total liabilities
- $61.0M
- Current liabilities
- $44.0M
- Shareholders’ equity
- $505.7M
Cash flow
- Operating cash flow
- -$109.1M
- Investing cash flow
- -$93.0M
- Financing cash flow
- $113.0M
- Net cash flow
- -$89.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $451.7M
- EPS (diluted)
- $-2.42
- Shares outstanding
- 52.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 11, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $140.1M in FY2025.
- Revenue grew 372% from FY2021 to FY2025.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review 4D Molecular Therapeutics, Inc..
Write a review
News about 4D Molecular Therapeutics, Inc.
News & sentiment via Polygon.io
